___

• Yazigi-Rivard L, Masserot C, Lachenaud J, Diebold- Pressac I, Aprahamian A, Avran D, Doz F. [Childhood 2008;15:1794-804 Arch Pediatr
• Brada M. Pathology and Genetics of Tumours of the Nervous System. Br J Cancer 2001;84:148
• Heideman RL, Packer RJ, Albright LA, Freeman CR, Rorke LB. Tumors of the central nervous system. In: Pizzo PA and Poplack DG, editors.Principles and Practice of Pediatric Oncology, 3rd edition. Philadelphia,USA: Philip, Lippincott-Raven, 1997
• Kun LE. Brain tumors in children. In: Perez CA and Brandy LW, editors. Principles and Practice of Radiation Oncology. 3rd Edition. Philadelphia,USA: Lippincott-Raven, 1997 HJ: 5. Bloom Medulloblastoma:
• prospects Int J Radiat Oncol Biol Phys 1977;2:1031- 1033 Prognosis and
• Dai CY, Nakamura JL, Haas-Kogan D. Central Nervous System. In: Hansen EK, Roach III M, editors. Handbook of evidence based radiation oncology. New York, NY: Springer; 2006:15-54
• Kun LE, Tarbell NJ. Current Treatment and Contraversies in Childhood Brain Tumors. In: ASTRO Education session. Atlanta, GA; 2004
• Polkinghorn WR, Tarbell NJ. Medulloblastoma: tumorigenesis, currentcinical paradigm, and efforts to improve risk stratification. Nat Clin Pract Oncol 2007;5:295-304
• Rood BR, Macdonald TJ, Packer RJ. Current treatment of medulloblastoma: Recent advances and future challenges. Semin Oncol 2004;31:666-75
• Vezina LG, Packer RJ. Infratentorial brain tumors of childhood. 1994;4:423-436 Clin North Am
• Packer RJ, Goldwein J, Nicholson HS, et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children’s Cancer Group Study. J Clin Oncol 1999;17:2127-36
• Yao MS, Mehta MP, Boyett JM, et al. The effect of M-stage on patterns of failure in posterior fossa pri- mitive neuroectodermal tumors treated on CCG-921: a phase III study in a high-risk patient population. Int J Radiat Oncol Biol Phys 1997;38:469-76
• Lamont JM, McManamy CS, Pearson AD, Clifford SC, Ellison DW. Combined histopathological and molecular medulloblastoma 2004;10:5482-93
• stratification Clin Res patients. Cancer
• Chintagumpala M, Berg S, Blaney SM. Treatment contraversies in medulloblastoma. Curr Opin Oncol 2001;13:154-9
• Zeltzer PM, Boyett JM, Finlay JL, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children’s Cancer Group 921 randomized phase III study. J Clin Oncol 1999;17:832-45
• Kühl J, Müller HL, Berthold F, et al. Pre-radiation chemotherapy of children and young adults with ma- lignant brain tumors: results of German pilot trial HIT’88/89. Klin Paeditr 1998;17:832-45
• Krischer JP, Ragap AH, Kun L, et al. Nitrogen mustard, vincristine, procarbazine and prednisone as adjuvan medulloblastoma. A Pediatric Oncology Group study. J Neurosurg 1991;74:905-9 in the treatment of
• Bailey CC, Gnekow A, Wellek S, et al. Prospective randomised trial of chemotherapy given before radiotherapy International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Med Pediatr Oncol 1995;25:166-78
• Evans AE, Jenkin RD, Sposto R, et al. The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg 1990;72:572-82
• Tait DM, Thornton-Jones H, Bloom HJ, Lemerle J, Morris medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I). Eur J Cancer 1990;26:464-9 for
• Schell MJ, McHaney VA, Green AA, et al. Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. J Clin Oncol 1989;7:754-60
• Ertaş G, Uçer AR, Altundag MB, Durmus S, Calikoglu T, Ozbagi K, Abanuz H, Altundag K, Demirkasimoglu neuroectodermal tumor in adults: prognostic factors and treatment results: a single-center experience from Turkey. Med Oncol 2008;25:69-72
• Thomas PR, Deutsch M, Kepner JL, et al. Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol 2000;18:3004-11
• St. Clair WH, Adams JA, Bues M, et al. Advantage of protons compared to conventional X-Ray or IMRT in the treatment of a pediatric patient with medulloblastoma. Int J Radiat Oncol Biol Phys 2004;38:727-34
• Jain N, Krull KR, Brouwers P, Chintagumpala MM, Woo SY. Neuropsychological outcome following intensity-modulated radiation therapy for pediatric medulloblastoma. Pediatr Blood Cancer 2008;51:275- 9
• Lin R, Hug EB, Schaefer BS, et al. Conformal proton radiation therapy of the posterior fossa: A study comparing protons with three-dimensional planned photons in limiting dose to auditory structures. Int J Radiat Oncol Biol Phys 2000;48:1219-26
• Parker W, Filion E, Roberge D, Freeman CR. Intensity-modulated radiotherapy for craniospinal irradiation: target volume considerations, dose constraints, and competing risks Int J Radiat Oncol Biol Phys. 2007;69:251-7
• Parker WA, Freeman CR. A simple technique for craniospinal radiotherapy in the supine position. Radiother Oncol 2006;78:217-22
• Liu M, Carrie C, Parker W, Freeman CR. Comprasion of manual and computer-generated customized blocks for whole brain fields used in the treatment of medulloblastoma. Med Pediatr Oncol 2002;38:55-7
• Carrie C, Hoffstetter S, Gomez F, et al. Impact of targeting medulloblastoma:Study of the French Society of Pediatric Oncology (SFOP).Int J Radiat Oncol Biol Phys 1999;45:435-9 on outcome in
• Hall EJ, Wuu CS. Radiation-induced second cancers:The impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 2003;56:83-8
• International Commission on Radiation Units and Measurements. Prescribing, recording, and reporting photon beam therapy. Bethesda, MD:ICRU;1999
• Survivors of Childhood Cancer: Assessment and Ma- nagement. St. Louis, Mo: Mosby; 1994.
• Brandes AA, Franceschi E, Tosoni A. Adult neuroectodermal (medulloblastoma) and of supratentorial sites (stPNET). Crit Rev Oncol Hematol 2009;71:165-79